William Blair Has Negative Forecast for Moderna Q2 Earnings

Moderna, Inc. (NASDAQ:MRNA) – Analysts at William Blair decreased their Q2 2025 earnings per share estimates for shares of Moderna in a research report issued on Monday, July 14th. William Blair analyst M. Minter now anticipates that the company will post earnings per share of ($2.77) for the quarter, down from their previous forecast of ($2.72). William Blair has a “Market Perform” rating on the stock. The consensus estimate for Moderna’s current full-year earnings is ($9.61) per share. William Blair also issued estimates for Moderna’s FY2026 earnings at ($8.37) EPS.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, beating analysts’ consensus estimates of ($2.92) by $0.40. Moderna had a negative return on equity of 28.69% and a negative net margin of 105.67%. The company had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. During the same period last year, the company earned ($3.07) earnings per share. The company’s quarterly revenue was down 35.3% compared to the same quarter last year.

A number of other brokerages have also weighed in on MRNA. Wells Fargo & Company reaffirmed an “equal weight” rating on shares of Moderna in a research note on Sunday. Morgan Stanley decreased their price target on Moderna from $39.00 to $32.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 9th. JPMorgan Chase & Co. dropped their price objective on Moderna from $33.00 to $26.00 and set an “underweight” rating on the stock in a research note on Thursday, May 22nd. Barclays restated an “equal weight” rating on shares of Moderna in a report on Sunday. Finally, UBS Group lowered their target price on Moderna from $78.00 to $70.00 and set a “buy” rating on the stock in a report on Friday, May 2nd. Four analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $46.61.

Moderna Stock Up 1.5%

Shares of MRNA opened at $32.06 on Wednesday. The firm has a market capitalization of $12.40 billion, a PE ratio of -3.67 and a beta of 1.84. The firm has a 50-day moving average price of $27.62 and a 200 day moving average price of $31.05. Moderna has a 52-week low of $23.15 and a 52-week high of $126.42.

Institutional Trading of Moderna

Large investors have recently added to or reduced their stakes in the company. S Bank Fund Management Ltd acquired a new stake in shares of Moderna in the first quarter worth $25,000. TD Private Client Wealth LLC lifted its stake in Moderna by 348.8% in the 2nd quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock worth $26,000 after acquiring an additional 743 shares in the last quarter. Crowley Wealth Management Inc. acquired a new stake in Moderna during the 4th quarter worth about $41,000. SVB Wealth LLC purchased a new position in Moderna during the 1st quarter valued at about $28,000. Finally, Itau Unibanco Holding S.A. increased its holdings in shares of Moderna by 51.2% in the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company’s stock valued at $42,000 after purchasing an additional 343 shares during the period. 75.33% of the stock is owned by institutional investors and hedge funds.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.